All In Biotech

Drug Trial Radar · NCT07911670

Exploratory Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Parkinson's Disease

Exploratory Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of UX-DA003 Injection (Human iPSC-derived Midbrain Dopaminergic Neural Precursor Cells) in Patients With Parkinson's Disease

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Nov 23, 2026

Primary completion

Mar 2029

Study completion Jun 2032

Sponsor

Lead sponsor
The First Affiliated Hospital of Anhui Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shanghai UniXell Biotechnology Co., Ltd
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 30 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study is designed to explore the safety and tolerability of UX-DA003. It will also explore if UX-DA003 works to improve motor function in subjects with Parkinson's disease.

Conditions

  • PARKINSON DISEASE (Disorder)

Interventions

  • UX-DA003Drug

    UX-DA003 (Human Allogeneic iPSC-derived Midbrain Dopaminergic Progenitor cells) is used for treating patients with PD via implanting into bilateral putamina under stereotactic neurosurgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: Within 6 months after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University Recruiting

    Hefei, Anhui, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.